ACS Combinatorial Science
RESEARCH ARTICLE
’ REFERENCES
J. Med. 1997, 337, 1641–1647. (b) Weatherman, R. V.; Carroll, D. C.;
Scanlan, T. S. Activity of a Tamoxifen-Raloxifene Hybrid Ligand for
Estrogen Receptors at an AP-1 Site. Bioorg. Med. Chem. Lett. 2001,
11, 3129–3131.
(13) Suh, N.; Glasebrook, A. L.; Palkowitz, A. D.; Bryant, H. U.;
Burris, L. L.; Starling, J. J.; Pearce, H. L.; Williams, C.; Peer, C.; Wang, Y.;
Sporn, M. B. Arzoxifene, A New Selective Estrogen Receptor Modulator
for Chemoprevention of Experimental Breast Cancer. Cancer Res. 2001,
61, 8412–8415.
(14) Qin, Z.; Kastrati, I.; Chandrasena, R. E. P.; Liu, H.; Yao, P.;
Petukhov, P. A.; Bolton, J. L.; Thatcher, G. R. J. Design and Synthesis
of Benzothiophene SERMs with Modulated Oxidative Activity and
Receptor Affinity. J. Med. Chem. 2007, 50, 2682–2692.
(15) Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G. J.;
Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato,
M.; Termine, J. D.; Winter, M. A.; Yang, N. N.; Dodge, J. A. Molecular
Determinants of Tissue Selectivity in Estrogen Receptor Modulators.
Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14105–14110.
(1) Lerner, L. J.; Holthaus, F. J., Jr.; Thompson, C. R. A Nonsteroidal
Estrogen Antagonist, 1-[p-(2-Diethylaminoethoxy)phenyl]-1-phenyl-
2-(p-methoxyphenyl)ethanol. Endocrinology 1958, 63, 295–318.
(2) Weatherman, R. V.; Fletterick, R. J.; Scanlan, T. S. Nuclear-
Receptor Ligands and Ligand-binding Domains. Annu. Rev. Biochem.
1999, 68, 559–581.
(3) Gustafsson, J. A. Therapeutic Potential of Selective Estrogen
Receptor Modulators. Curr. Opin. Chem. Biol. 1998, 2, 508–511.
(4) (a) Harper, M. J.; Walpole, A. L. Contrasting Endocrine Activ-
ities of cis and trans Isomers in a Series of Substituted Triphenylethy-
lenes. Nature 1966, 212, 87. (b) Jordan, V. C.; Phelps, E.; Lindgren, J. U.
Effects of anti-Estrogens on Bone in Castrated and Intact Female Rats.
Breast Cancer Res. Tr. 1987, 10, 31–35. (c) Jordan, V. C. Tamoxifen: A
Most Unlikely Pioneering Medicine. Nat. Rev. Drug Discovery 2003,
2, 205–213. (d) Itami, K.; Kamei, T.; Yoshida, J. Diversity-Oriented
Synthesis of Tamoxifen-Type Tetrasubstituted Olefins. J. Am. Chem. Soc.
2003, 125, 14670–14671.
(16) (a) Richardson, T. I.; Frank, S. A.; Wang, M.; Clarke, C. A.;
Jones, S. A.; Ying, B.-P.; Kohlman, D. T.; Wallace, O. B.; Shepherd, T. A.;
Dally, R. D.; Palkowitz, A. D.; Geiser, A. G.; Bryant, H. U.; Henck, J. W.;
Cohen, I. R.; Rudmann, D. G.; McCann, D. J.; Coutant, D. E.; Oldham,
S. W.; Hummel, C. W.; Fong, K. C.; Hinklin, R.; Lewis, G.; H., T.; D. J.,
A. Structure-Activity Relationships of SERMs Optimized for Uterine
Antagonism and Ovarian Safety. Bioorg. Med. Chem. Lett. 2007, 17,
3544–3549. (b) Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.;
Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler,
P. K.; Cullinan, G. J.; Pell, T. R.; Bryant, H. U. Discovery and Synthesis
of [6-Hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxy-
phenyl)]benzo[b]thiophene: A Novel, Highly Potent, Selective Estro-
gen Receptor Modulator. J. Med. Chem. 1997, 40, 1407–1416. (c) Grese,
T. A.; Cho, S.; Finley, D. A.; Godfrey, A. G.; Jones, C. D.; Lugar, C. W. I.;
Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian,
M. D.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short,
L. L.; Glasebrook, A. L.; Bryant, H. U. Structure-Activity Relationships of
Selective Estrogen Receptor Modulators: Modifications to the 2-Aryl-
benzothiophene Core of Raloxifene. J. Med. Chem. 1997, 40, 146–167.
(d) Yu, L.; Liu, H.; Li, W.; Zhang, F.; Luckie, C.; van Breemen, R. B.;
Thatcher, G. R. J.; Bolton, J. L. Oxidation of Raloxifene to Quinoids:
Potential Toxic Pathways via a Diquinone Methide and o-Quinones.
Chem. Res. Toxicol. 2004, 17, 879–888. (e) Grese, T. A.; Pennington,
L. D.; Sluka, J. P.; Adrian, M. D.; Cole, H. W.; Fuson, T. R.; Magee, D. E.;
Phillips, D. L.; Rowley, E. R.; Shetler, P. K.; Short, L. L.; Venugopalan,
M.; Yang, N. N.; Sato, M.; Glasebrook, A. L.; Bryant, H. U. Synthesis and
Pharmacology of Conformationally Restricted Raloxifene Analogues:
Highly Potent Selective Estrogen Receptor Modulators. J. Med. Chem.
1998, 41, 1272–1283. (f) Schmid, C. R.; Sluka, J. P.; Duke, K. M.
Nucleophilic Aromatic Substitution on 3-Aroyl-2-arylbenzothiophenes.
Rapid Access to Raloxifene and Other Selective Estrogen Receptor
Modulators. Tetrahedron Lett. 1999, 40, 675–678.
(17) (a) Macgregor, J. I.; Jordan, V. C. Basic Guide to the Mech-
anisms of Antiestrogen Action. Pharmacol. Rev. 1998, 50, 151–196.
(b) Bolton, J. L.; Yu, L.; Thatcher, G. R. J. Quinoids Formed from
Estrogens and Antiestrogens. Methods Enzymol. 2004, 378, 110–123.
(18) (a) Bianchini, C.; Meli, A. Thiophene, Benzo[b]thiophene and
Dibenzo[b,d]thiophene as Precursors to Highly Conjugated Organo-
sulfur Compounds. Synlett 1997, 643–649. (b) Irie, M.; Uchida, K.
Synthesis and Properties of Photochromic Diarylethenes with Hetero-
cyclic Aryl Groups. Bull. Chem. Soc. Jpn. 1998, 71, 985–996. (c) Zhang,
T. Y.; O’Toole, J.; Proctor, C. S. Recent Advances in the Synthesis
and Applications of Benzo[b]thiophenes. Sulfur Rep. 1999, 22, 1–47.
(d) Pelkey, E. T. Five-Membered Ring Systems: Thiophenes & Se,
Te Analogs. Prog. Heterocycl. Chem. 2003, 15, 116–139.
(5) Killackey, M. A.; Hakes, T. B.; Pierce, V. K. Endometrial
Adenocarcinoma in Breast Cancer Patients Receiving Antiestrogens.
Cancer Treat. Rep. 1985, 69, 237–238.
(6) (a) Lloyd, D. G.; Hughes, R. B.; Zisterer, D. M.; Williams, D. C.;
Fattorusso, C.; Catalanotti, B.; Campiani, G.; Meegan, M. J. Benzoxepin-
Derived Estrogen Receptor Modulators: A Novel Molecular Scaffold for
the Estrogen Receptor. J. Med. Chem. 2004, 47, 5612–5615. (b) Carta,
G.; Knox, A. J. S.; Lloyd, D. G. Unbiasing Scoring Functions: A New
Normalization and Rescoring Strategy. J. Chem. Inf. Model. 2007, 47,
1564–1571.
(7) Blizzard, T. A.; Morgan, J. D.; Mosley, R. T.; Birzin, E. T.; Frisch,
K.; Rohrer, S. P.; Hammond, M. L. 2-Phenylspiroindenes: A Novel Class
of Selective Estrogen Receptor Modulators (SERMs). Bioorg. Med.
Chem. Lett. 2003, 13, 479–483.
(8) (a) Greenberger, L. M.; Annable, T.; Collins, K. I.; Komm, B. S.;
Lyttle, C. R.; Miller, C. P.; Satyaswaroop, P. G.; Zhang, Y.; Frost, P. A
New Antiestrogen, 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-
1-yl-ethoxy)-benzyl]-1H-indol-5-ol Hydrochloride (ERA-923), Inhibits
the Growth of Tamoxifen-sensitive and -resistant Tumors and is Devoid
of Uterotropic Effects in Mice and Rats. Clin. Cancer Res. 2001, 7,
3166–3177. (b) Miller, C. P.; Collini, M. D.; Tran, B. D.; Harris, H. A.;
Kharode, Y. P.; Marzolf, J. T.; Moran, R. A.; Henderson, R. A.; Bender,
R. H. W.; Unwalla, R. J.; Greenberger, L. M.; Yardley, J. P.; Abou-
Gharbia, M. A.; Lyttle, C. R.; Komm, B. S. Design, Synthesis, and
Preclinical Characterization of Novel, Highly Selective Indole Estrogens.
J. Med. Chem. 2001, 44, 1654–1657.
(9) (a) Steinbaum, F. L.; De Jager, R.; Krakoff, I. Clinical Trial of
Nafoxidine in Advanced Breast Cancer. Med. Pediatr. Oncol. 1978, 4,
123–126. (b) Castaner, J.; Thorpe, P. Nafoxidine. Drugs Future 1978,
3, 211–215. (c) Legha, S. S.; Slavik, M.; Carter, S. K. Nafoxidine - An
Antiestrogen for the Treatment of Breast Cancer. Cancer 1976, 38,
1535–1541. (d) Laios, I.; Journe, F.; Laurent, G.; Nonclercq, D.; Toillon,
R.-A.; Seo, H.-S.; Leclercq, G. Mechanisms Governing the Accumulation
of Estrogen Receptor Alpha in MCF-7 Breast Cancer Cells Treated with
Hydroxytamoxifen and Related Antiestrogens. J. Steroid Biochem. Mol.
Biol. 2004, 87, 207–221.
(10) Neubauer, B. L.; McNulty, A. M.; Chedid, M.; Chen, K.;
Goode, R. L.; Johnson, M. A.; Jones, C. D.; Krishnan, V.; Lynch, R.;
Osborne, H. E.; Graff, J. R. The Selective Estrogen Receptor Modulator
Trioxifene (LY133314) Inhibits Metastasis and Extends Survival in the
PAIII Rat Prostatic Carcinoma Model. Cancer Res. 2003, 63, 6056–6062.
(11) Liu, H.; Liu, J.; van Breemen, R. B.; Thatcher, G. R. J.; Bolton,
J. L. Bioactivation of the SERM Desmethylated Arzoxifene to Quinoids:
40-Fluoro Substitution Prevents Quinoid Formation. Chem. Res. Toxicol.
2005, 18, 162–173.
(12) (a) Delmas, P. D.; Bjarnason, N. H.; Mitlak, B. H.; Ravoux,
A.-C.; Shah, A. S.; Huster, W. J.; Draper, M.; Christiansen, C. Effects of
Raloxifene on Bone Mineral Density, Serum Cholesterol Concentra-
tions, and Uterine Endometrium in Postmenopausal Women. N. Engl.
(19) (a) Yue, D.; Larock, R. C. Synthesis of 2,3-Disubstituted
Benzo[b]thiophenes via Palladium-Catalyzed Coupling and Elec-
trophilic Cyclization of Terminal Acetylenes. J. Org. Chem. 2002, 67,
1905–1909. (b) Cho, C.-H.; Neuenswander, B.; Lushington, G. H.;
Larock, R. C. Solution-Phase Parallel Synthesis of a Multi-substituted
509
dx.doi.org/10.1021/co200090p |ACS Comb. Sci. 2011, 13, 501–510